1.A mixed study of the needs of patients with post-stroke cognitive impairment no dementia
Meng JIAO ; Peiyu ZHAO ; Yan XU ; Si GAO ; Xudong HE ; Jianni QU ; Hong GUO
Chinese Journal of Practical Nursing 2024;40(14):1105-1114
Objective:To understand the health needs of patients with non-dementia cognitive impairment after stroke, to provide reference for targeted interventions.Methods:Using the convergent mixed research method, convenience sampling was used to select post-stroke patients with non-dementia cognitive impairment in China-Japan Friendship Hospital and Beijing University of Chinese Medicine Third Affiliated Hospital, a cross-sectional survey was conducted on 191 patients with non-dementia cognitive impairment after stroke using the health needs questionnaire in March to August 2023. A descriptive study was used to conduct semi-structured interviews with 16 patients.Results:A total of 191 questionnaires were distributed and 191 valid questionnaires were collected, including 103 male and 88 female patients, aged from 34 to 90 years old. The items of the post-stroke health questionnaire were (3.47 ± 0.54), with the highest need for understanding the rehabilitation program (148/191); multiple linear regression analysis showed that gender and primary caregiver type were factors influencing their health needs ( t = 2.39, 2.73, both P<0.05). A total of 16 patients with non-dementia cognitive impairment after stroke, 10 males and 6 females, aged from 58 to 90 years old, were interviewed. Four themes were extracted, namely, information support and behavioral guidance needs, psychological care needs, social support needs, and pre-established medical care plan needs. Conclusions:The health needs of patients with non-dementia cognitive impairment after stroke are at an above medium level and have diversified characteristics. Medical staff should conduct systematic health management based on patients′specific conditions and actual needs to help patients recover or maintain cognitive function.
3.A Meta-analysis of the incidence of falls in the frail elderly population
Yanmei CHEN ; Hong GUO ; Meng JIAO ; Si GAO ; Li LI ; Qiong WU ; Qing WANG ; Yueyuan BAI
Chinese Journal of Practical Nursing 2024;40(16):1275-1281
Objective:To analyze and evaluate the current situation of falls in the frail elderly population, and to provide a reliable basis for formulating measures for fall prevention.Methods:CNKI, VIP Database, Wanfang Database, China Biomedical Database, PubMed, Embase, Web of Science, CINAHL, Cochrane Library, Sinomed were searched, and cross-sectional studies on falls in the frail elderly population were searched, and the search time limit was established until June 30, 2023. Two review authors independently screened studies, extracted data, assessed the risk of bias of included studies, and Meta-analyses were performed using Stata 16.0 software and RevMan5.4.Results:A total of 12 cross-sectional studies with a total sample size of 4 597 cases were included. Meta-analysis showed that the incidence of falls in the frail elderly population was 39.9% (1 834/4 597). The results of subgroup analysis showed that there was significant difference in the female, age, chronic pain, body mass index, live alone ( P<0.05). The incidence of falls in male and female was 25.9%(640/2 471) and 40.7%(1 005/2 471), respectively. The incidence of falls in the aged 60-69, 70-79 and over 80 years old was 25.7%(470/1 831), 30.6% (560/1 831) and 46.8%(857/1 831), respectively. The incidence of falls in body mass index < 18.5, 18.5-24.0, >24.0 kg/m 2 was 12.29%(63/512), 9.58%(49/512) and 19.89%(101/512), respectively. The incidence of falls in with or without chronic pain was 33.55%(181/541) and 16.03%(87/541), respectively. The incidence of falls in living alone and not living alone was 32.3%(524/1 624) and 16.9%(274/1 624), respectively. Conclusions:The incidence of falls in the frail elderly population is at a relatively high level. Women, older adults, overweight, have chronic pain and live alone have a higher incidence of falls.
4.Development of a GeXP assay for simultaneous differentiation of the H7 subtype and five NA subtypes of avian influenza viruses
Si-Si LUO ; Zhi-Xun XIE ; Meng LI ; Dan LI ; Li-Ji XIE ; Sheng WANG ; Min-Xiu ZHANG ; Jiao-Ling HUANG ; Zhi-Qin XIE ; Ting-Ting ZENG ; Yan-Fang ZHANG
Chinese Journal of Zoonoses 2024;40(7):670-677
Cases of human infection with H7 subtype avian influenza virus(AIV)combined with five NA subtypes(N2,N3,N4,N7,and N9)have been reported.This study was aimed at establishing a method for simultaneous detection and dif-ferential diagnosis of H7 and five NA subtypes of AIV.Seven pairs of specific primers were designed according to the conserved sequences of the HA gene of H7 subtype AIV,the NA gene of five NA AIV subtypes,and the M gene of all AIV subtypes.A high-throughput GeXP typing method was established for simultaneous detection of the H7 subtype and the five NA subtypes of AIV by using GeXP multiple gene expression and capillary electrophoresis analysis technology.The specificity and sensitivity of the method were determined,and clinical samples were tested.The specificity results indicated that this method was able to simultaneously detect seven target genes in a single tube;each pair of specific primers was able to detect the corresponding AIV subtype,and the universal detection primers were able to detect all subtypes of AIV,with no cross-reaction with other common avian disease pathogens.Sensitivity results demonstrated that this method was able to simultaneously detect seven target genes with a threshold detection limit was 100 copies/μL.The detection results for 150 clinical samples were consistent with those of viral isolation and identification.The high-throughput GeXP method for simultaneous differential diagnosis of the H7 subtype and five subtypes of AIV established in this study has advantages of high specificity,high sensitivity,rapidity,and simplicity,thus providing a new detection method for the effective prevention and control of AIV.
5.Study on Inclusion Behavior of Carbendazim with Cyclodextrins
Wei SUN ; Meng-Yao SHE ; Si-Yue MA ; Jiao CHEN ; Zhen SHI ; Jian-Li LI
Chinese Journal of Analytical Chemistry 2018;46(2):246-253,后插5-后插10
Hydrophobic medicine carbendazim,come into inclusion compounds with β-cyclodextrin(β-CD),2-hydroxypropyl-β-CD (2-Hp-β-CD) and 2,6-dimethyl-β-CD(Me-β-CD),were made by solvent method.By investigating the inclusion behaviors of these three cyclodextrins combined with carbendazim using 1H NMR,2D rotating frame overhause effect spectroscopy (ROESY) and diffusion ordered spectroscopy,the possible ways of combinations and the recognition ratio of this three inclusion compounds,Dβ-CD=2.516×10-10m2/s,D2-Hp-β-CD=1.676×10-10m2/s,DMe-β-CD=2.046×10-10m2/s,were obtained.According to X-ray power diffraction,thermogravimetric analysis,infrared spectroscopy and scanning electron spectroscopy characterization,it was found that the characteristic diffraction peaks changed after carbendazim and cyclodextrin formed into inclusion compounds,and the characteristic diffraction peak of carbendazim at 10.4°,21.2°,25.8°,31.5°(2θ) lost or disappear.The pyrolysis temperature of carbendazim was 197.5℃,and would be higher than 260℃ after it formed inclusion complex.The infrared spectrum also showed that the oscillation peaks of inner cyclodextrin cavum apparently reduced after carbendazim combined,which demonstrated that the position of water molecules inside cyclodextrin cavum were occupied by the carbendazim molecules.With the help of SEM,the appearances of inclusion were different from a single carbendazim molecule,which manifested a new structure appeared.
6.Research status of pharmacological mechanism of PCSK9 inhibitors and discussion of their clinical application
Wen-Hui MO ; Si-Lei XU ; Xia HE ; Niu-Niu BAI ; Meng-Ying YUAN ; Zhi-Min LI ; Jiao ZHANG ; Fei WANG ; Yuan-Kun ZHENG
The Chinese Journal of Clinical Pharmacology 2024;40(16):2438-2441
Atherosclerosis caused by disorders of lipid metabolism is the main pathological basis of atherosclerotic cardiovascular disease.Statins are the cornerstone of lipid-modulating therapy for this type of disease,but in practice there are still some patients with suboptimal lipid management.Proprotein convertase subtilisin/kexin type 9(PCSK9)inhibitors have been gradually applied as a new class of lipid-modulating drugs for the treatment in patients with this type of disease,and recent studies have shown that in addition to regulating lipid metabolism,PCSK9 inhibitors also have potential anti-inflammatory and anti-platelet activation effects.This article sorts out the multiple pharmacological mechanisms of action of PCSK9 inhibitors and the current status of clinical research of PCSK9 inhibitors.Besides,it discusses the factors that may affect the efficacy of PCSK9 inhibitors,in order to provide a reference for the safe and rational medication of PCSK9 inhibitors.
7.The role of the high-level public health school in the development of the Center for Disease Control and Prevention.
He Xiang PENG ; Si Yue WANG ; Meng Ying WANG ; Xue Heng WANG ; Meng FAN ; Huang Da GUO ; Tian Jiao HOU ; Yuan Tao HAO ; Tao REN ; Tao WU
Chinese Journal of Epidemiology 2023;44(4):662-666
The Ministry of Education and other four departments jointly issued the Notice on the Construction of high-level schools of public Health, proposing that "it will take ten years to build a number of high-level schools of public health, and form a high-quality education development system to adapt to the construction of modern public health system". At present, the construction of high-level public health schools in various universities in China is in full swing. The high-level School of Public Health and the CDC have played an important role in constructing the national public health system and the human health community. The high-level public health schools are of strategic significance and important value to the development of the CDC. The review presents reflections and insights on the role of high-level public health schools in the development of the CDC and the challenges they might face.
Humans
;
United States
;
Schools, Public Health
;
Schools
;
Universities
;
Public Health
;
Centers for Disease Control and Prevention, U.S.
8.Effects of extramedullary disease on patients with newly diagnosed multiple myeloma.
Yi TAO ; Shi Wei JIN ; Yan WANG ; Si Jie TANG ; Yuan Fang LIU ; Jie XU ; Meng Meng PAN ; Wei Ping ZHANG ; Jian Qing MI
Chinese Journal of Hematology 2023;44(1):48-54
Objective: To summarize the characteristics of patients with newly diagnosed multiple myeloma (NDMM) admitted at Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine. We compared the clinical characteristics and prognoses among patients with non-extramedullary disease (EMD), bone-related extramedullary (EM-B) disease, and extraosseous extramedullary (EM-E) disease and further explored the effects of autologous hematopoietic stem cell transplantation (ASCT) for EMD. Methods: From January 2015 to January 2022, data of 114 patients (22%) with EMD out of 515 patients with NDMM were retrospectively analyzed; 91 (18%) and 23 (4%) patients comprised the EM-B and EM-E groups, respectively. The clinical characteristics of patients in all groups were compared with the Chi-square test. Progression-free survival (PFS) and overall survival (OS) of patients were analyzed by the Kaplan-Meier method. Independent prognostic factors were determined using multivariate Cox proportional hazard model. Results: There were no significant differences in age, gender, ISS stage, light chain, creatinine clearance, cytogenetic risk, 17p deletion, ASCT, and induction regimens among the three groups. Overall, 13% of EM-E patients had IgD-type M protein, which was significantly higher than that in EM-B patients (P=0.021). The median PFS of patients in the non-EMD, EM-B, and EM-E groups was 27.4, 23.1, and 14.0 months; the median OS was not reached, 76.8 months, and 25.6 months, respectively. The PFS (vs non-EMD, P=0.004; vs EM-B, P=0.036) and OS (vs non-EMD, P<0.001; vs EM-B, P=0.002) were significantly worse in patients with EM-E, while those were not significantly different between patients with EM-B and those with non-EMD. In the multivariate analysis, EM-E was an independent prognostic factor for OS in patients with NDMM (HR=8.779, P<0.001) and negatively impacted PFS (HR=1.874, P=0.050). In those who did not undergo ASCT, patients with EM-B had significantly worse OS than those with non-EMD (median 76.8 months vs. not reached, P=0.029). However, no significant difference was observed in the PFS and OS of patients with EM-B and those with non-EMD who underwent ASCT. Conclusions: Compared to patients with either non-EMD or EM-B, those with EM-E had the worst prognosis. EM-E was an independent risk factor for OS in patients with NDMM. ASCT can overcome the poor prognosis of EM-B.
Humans
;
Multiple Myeloma/therapy*
;
Retrospective Studies
;
China
;
Hematopoietic Stem Cell Transplantation
;
Prognosis
;
Transplantation, Autologous
9.Efficiency and safety analysis of Plerixafor combined with granulocyte colony-stimulating factor on autologous hematopoietic stem cell mobilization in lymphoma.
Meng Meng JI ; Yi Ge SHEN ; Ji Chang GONG ; Wei TANG ; Xiao Qian XU ; Zhong ZHENG ; Si Yuan CHEN ; Yang HE ; Xin ZHENG ; Lin Di ZHAO ; Wei Lin ZHAO ; Wen WU
Chinese Journal of Hematology 2023;44(2):112-117
Objective: To evaluate the advantages and safety of Plerixafor in combination with granulocyte colony-stimulating factor (G-CSF) in autologous hematopoietic stem cell mobilization of lymphoma. Methods: Lymphoma patients who received autologous hematopoietic stem cell mobilization with Plerixafor in combination with G-CSF or G-CSF alone were obtained. The clinical data, the success rate of stem cell collection, hematopoietic reconstitution, and treatment-related adverse reactions between the two groups were evaluated retrospectively. Results: A total of 184 lymphoma patients were included in this analysis, including 115 cases of diffuse large B-cell lymphoma (62.5%) , 16 cases of classical Hodgkin's lymphoma (8.7%) , 11 cases of follicular non-Hodgkin's lymphoma (6.0%) , 10 cases of angioimmunoblastic T-cell lymphoma (5.4%) , 6 cases of mantle cell lymphoma (3.3%) , and 6 cases of anaplastic large cell lymphoma (3.3%) , 6 cases of NK/T-cell lymphoma (3.3%) , 4 cases of Burkitt's lymphoma (2.2%) , 8 cases of other types of B-cell lymphoma (4.3%) , and 2 cases of other types of T-cell lymphoma (1.1%) ; 31 patients had received radiotherapy (16.8%) . The patients in the two groups were recruited with Plerixafor in combination with G-CSF or G-CSF alone. The baseline clinical characteristics of the two groups were basically similar. The patients in the Plerixafor in combination with the G-CSF mobilization group were older, and the number of recurrences and third-line chemotherapy was higher. 100 patients were mobilized with G-CSF alone. The success rate of the collection was 74.0% for one day and 89.0% for two days. 84 patients in the group of Plerixafor combined with G-CSF were recruited successfully with 85.7% for one day and 97.6% for two days. The success rate of mobilization in the group of Plerixafor combined with G-CSF was substantially higher than that in the group of G-CSF alone (P=0.023) . The median number of CD34(+) cells obtained in the mobilization group of Plerixafor combined with G-CSF was 3.9×10(6)/kg. The median number of CD34(+) cells obtained in the G-CSF Mobilization group alone was 3.2×10(6)/kg. The number of CD34(+) cells collected by Plerixafor combined with G-CSF was considerably higher than that in G-CSF alone (P=0.001) . The prevalent adverse reactions in the group of Plerixafor combined with G-CSF were grade 1-2 gastrointestinal reactions (31.2%) and local skin redness (2.4%) . Conclusion: The success rate of autologous hematopoietic stem cell mobilization in lymphoma patients treated with Plerixafor combined with G-CSF is significantly high. The success rate of collection and the absolute count of CD34(+) stem cells were substantially higher than those in the group treated with G-CSF alone. Even in older patients, second-line collection, recurrence, or multiple chemotherapies, the combined mobilization method also has a high success rate of mobilization.
Humans
;
Granulocyte Colony-Stimulating Factor/therapeutic use*
;
Hematopoietic Stem Cell Mobilization/methods*
;
Hematopoietic Stem Cell Transplantation
;
Heterocyclic Compounds/adverse effects*
;
Lymphoma/drug therapy*
;
Lymphoma, T-Cell/therapy*
;
Multiple Myeloma/drug therapy*
;
Retrospective Studies
;
Transplantation, Autologous
10. FOXA2 improves liver function and blood lipid levels in mice with intrahepatic cholestasis and hyperlipidemia
Meng-Jie ZHANG ; Xiao-Ming YANG ; Miao YU ; Yi JIAO ; Yang YANG ; Hui CHEN ; Si-Cong CHEN ; Hua-Li ZHAI ; Xiao-Ming YANG ; Miao YU
Chinese Pharmacological Bulletin 2021;37(11):1593-1599
Aim To study the regulatory effect of FOXA2 on liver function and blood lipid levels in mice with intrahepatic cholestasis and hyperlipidemia. Methods The model was constructed by feeding high cholesterol/cholic acid (CAD), and the FOXA2 plasmid was injected into the liver of mice by tail vein hypertension, so that the hepatocytes overexpressed F0XA2. The automatic blood biochemical analyzer was uses to detect the blood biochemical indicators of the serum, the colorimetric method to detect the cholesterol level in liver, and ELISA method to detect the liver bile acid level. Western blot was used to determine the expression of liver FOXA2, and RT-PCR to assess the mRNA expression of genes related to bile acid metabolism. H&E and oil red staining were employed to observe liver pathology. Results With the extension feeding time of the CAD, the weight of the mice continued to decrease (P < 0.01), the gallbladder increased significantly (P < 0.01), and the level of transaminase increased, and serum cholesterol and low-density lipoprotein cholesterol (P < 0.01) increased significantly. Liver tissue structure was damaged, liver cholesterol was elevated (P <0.01), bile acid level increased (P < 0.01), and lipid accumulation was serious. Overexpression of FOXA2 could significantly improve liver function and dyslipidemia in CAD-fed mice by regulating liver bile acid metabolism genes, and reduce liver bile acid levels (P < 0.01) and liver lipid accumulation. Conclusions FOXA2 improves liver function and blood lipid levels in mice with intrahepatic cholestasis and hyperlipidemia.